{"about":{"site":"https://codewithpapers.app","non_affiliation":"Code with Papers and Syntology are not affiliated with, endorsed by, or sponsored by Papers with Code, Meta, or the pwc-archive mirror.","licence":"CC BY-SA 4.0","licence_url":"https://creativecommons.org/licenses/by-sa/4.0/legalcode","attribution":"https://codewithpapers.app/attribution","modified":"archive material modified by Syntology; see the attribution page"},"url":"/paper/dccov-repositioning-of-drugs-and-drug","title":"DCcov: Repositioning of Drugs and Drug Combinations for SARS-CoV-2 Infected Lung through Constraint-Based Modelling","arxiv_id":"2103.13844","date":"2021-03-25","proceeding":null,"authors":["Ali Kishk","Maria Pires Pacheco","Thomas Sauter"],"abstract":"The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no effective antiviral drug except treatments for symptomatic therapy. Flux balance analysis is an efficient method to analyze metabolic networks. It allows optimizing for a metabolic function and thus e.g., predicting the growth rate of a specific cell or the production rate of a metabolite of interest. Here flux balance analysis was applied on human lung cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to reposition metabolic drugs and drug combinations against the replication of the SARS-CoV-2 virus within the host tissue. Making use of expression data sets of infected lung tissue, genome-scale COVID-19-specific metabolic models were reconstructed. Then host-specific essential genes and gene-pairs were determined through in-silico knockouts that permit reducing the viral biomass production without affecting the host biomass. Key pathways that are associated with COVID-19 severity in lung tissue are related to oxidative stress, as well as ferroptosis, sphingolipid metabolism, cysteine metabolism, and fat digestion. By in-silico screening of FDA approved drugs on the putative disease-specific essential genes and gene-pairs, 45 drugs and 99 drug combinations were predicted as promising candidates for COVID-19 focused drug repositioning (https://github.com/sysbiolux/DCcov). Among the 45 drug candidates, six antiviral drugs were found and seven drugs that are being tested in clinical trials against COVID-19. Other drugs like gemcitabine, rosuvastatin and acetylcysteine, and drug combinations like azathioprine-pemetrexed might offer new chances for treating COVID-19.","url_abs":"https://arxiv.org/abs/2103.13844v1","url_pdf":"https://arxiv.org/pdf/2103.13844v1.pdf","source":{"archive":"pwc-archive (Hugging Face), CC BY-SA 4.0","snapshot":"2025-07-28","licence_url":"https://creativecommons.org/licenses/by-sa/4.0/legalcode","row_kind":"abstracts"},"code_links":[{"paper_slug":"dccov-repositioning-of-drugs-and-drug","repo_url":"https://github.com/sysbiolux/DCcov","is_official":1,"mentioned_in_paper":1,"mentioned_in_github":1,"framework":"none","reach":null}],"tasks":[],"methods":[],"datasets_introduced":[],"methods_introduced":[],"results":[],"syntology":{"syntology_url":null,"atlas_url":null,"mcp":null,"developers":"https://syntology.ai/developers"},"arxiv_metadata":null,"syntology_extracted_results":null}